Antimicrobial drug use and resistance among respiratory pathogens in the community

Clinical Infectious Diseases

Volumn 33, Issue SUPPL. 3, 2001, Pages

  Low, D E ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; ERYTHROMYCIN; ETHAMBUTOL; ISONIAZID; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; VANCOMYCIN;

ADAPTATION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL FLORA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG EFFECT; DRUG MISUSE; DRUG USE; GENE TRANSFER; GENETIC CODE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 0035884744     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321849     Document Type: Conference Paper

References (91)

1. Controversies in the prevention and control of antimicrobial drug resistance
2. Action on antimicrobial resistance: Not easy, but Europe can do it
3. Antimicrobial resistance: Is a major threat to public health
4. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System
5. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study
6. Low dosage and long treatment duration of β-lactam: Risk factors for the carriage of penicillin-resistant Streptococcus pneumoniae
7. Inappropriateness and variability of antibiotic prescription among French office-based physicians
8. Trends in antimicrobial drug use in the community: France, 1981-1992
9. Mutation frequencies and antibiotic resistance
10. Inactivation of antibiotics and the dissemination of resistance genes
11. The Garrod Lecture: Evasion of antibiotic action by bacteria
12. Distribution of fitness effects caused by random insertion mutations in Escherichia coli
13. Reducing antibiotic resistance
14. The cost of antibiotic resistance: From the perspective of a bacterium
15. Evolution of bacteria/plasmid association
16. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae
17. Persistence of tetracycline resistance in pig E. coli
18. The population genetics of antibiotic resistance
19. Why are antibiotic resistance genes so resistant to elimination?
20. Antibiotic resistance: Counting the cost
21. To be a mutator, or how pathogenic and commensal bacteria can evolve rapidly
22. Microbial genetics, the tinkerer's evolving tool-box
23. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli
24. Evolution of high mutation rates in experimental populations of E. coli
25. High mutation frequencies among Escherichia coli and Salmonella pathogens
26. Shared themes of antigenic variation and virulence in bacterial, protozoal, and fungal infections
27. Life in the balance: Cell walls and antibiotic resistance
28. Multiply resistant pneumococcus causing meningitis: Its epidemiology within a day-care centre
29. Colonization with penicillin-resistant Streptococcus pneumoniae in a childcare center
30. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae
31. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s
32. Prophylaxis with amoxicillin or sulfamethoxazole for otitis media: Effect on recovery of penicillin resistant bacteria from children
33. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross-sectional prevalence study
34. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee
35. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio
36. Resistant pneumococci: Protecting patients through judicious use of antibiotics
37. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance
38. Antibiotic use in humans and bacterial resistance
39. Decline of erythromycin resistance of group A streptococci in Japan
40. Decline of erythromycin resistance of group A beta-hemolytic streptococci in Japan. Comparison with worldwide reports
41. Drug resistance in Streptococcus pyogenes strains isolated in Japan
42. Present and future in antibiotic treatment in pediatric patients
43. Resistance to erythromycin in group A streptococci
44. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland
45. Presence of ROB-1 beta-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae
46. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997)
47. Antibiotic resistance in respiratory tract isolates of haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998
48. Canadian Bacterial Surveillance Network, Low DE. A cross Canada surveillance of antimicrobial resistance in respiratory rract pathogens
49. Antibiotic susceptibility of blood and cerebrospinal fluid isolates of Haemophilus influenzae
50. Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada
51. Determination of antimicrobial susceptibility of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases
52. Broth dilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth
53. Ampicillin-resistant Haemophilus influenzae type B possessing a TEM-type beta-lactamase but little permeability barrier to ampicillin
54. Nucleotide sequence comparisons of plasmids pHD131, pJB1, pFA3, and pFA7 and beta-lactamase expression in Escherichia coli, Haemophilus influenzae, and Neisseria gonorrhoeae
55. Molecular nature of two beta-lactamase-specifying plasmids isolated from Haemophilus influenzae type b
56. Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998
57. BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata
58. Evolving resistance patterns of Streptococcus pneumoniae: A link with long-acting macrolide consumption?
59. Impact of azithromycin on oropharyngeal carriage of group A Streptococcus and nasopharyngeal carriage of macrolide-resistant Streptococcus pneumoniae
60. Mechanism of fluoroquinolone action
61. Fluoroquinolone resistance in Neisseria gonorrhoeae
62. Ciprofloxacin resistance in gonococci
63. Alterations within the quinolone resistance-determining regions of GyrA and Parc of Neisseria gonorrhoeae isolated in the Far East and the United States
64. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America
65. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study
66. Will pneumococci put quinolones in their place?
67. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
68. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d
69. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
70. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
71. Fluoroquinolone resistance in Streptococcus pneumoniae
72. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
73. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland
74. The specific polysaccharide content of pneumonic lungs
75. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
76. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae
77. Levofloxacin treatment failure of pneumococcal pneumonia and development of resistance during therapy
78. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: Different patterns of quinolone- induced inhibition of DNA synthesis
79. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
80. Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY Antimicrobial Surveillance Program (1998)
81. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC
82. Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin
83. Lower respiratory tract infection due to ciprofloxacin resistant Moraxella catarrhalis
84. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)
85. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
86. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
87. Pharmacodynamics of fluoroquinolones
88. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration
89. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
90. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae
91. New uses for new and old quinolones and the challenge of resistance